





LUPIN LTD

9 AUGUST 2024


About company

Lupin, headquartered in Mumbai, is an innovation-driven transnational pharmaceutical company. It develops and commercializes a broad range of branded and generic formulations, biotechnology products, and APIs across over 100 markets, including the U.S., India, South Africa, and the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company is engaged in the global development and marketing of generic formulations, biotechnology products, and APIs. Lupin holds a significant presence in segments such as Cardiovascular, Diabetology, Asthma, Pediatrics, and the Central Nervous System, and is a global leader in the Anti-TB and Cephalosporins segments.

Financials



MARKET CAP	RS 87,090 CR
P/E RATIO	46.0
DIVIDEND YIELD	0.43 %
ROCE	15.7%
ROE	14.1%
FACE VALUE	2.00
3 YEARS SALES GROWTH	10%
3 YEARS PROFIT GROWTH	17%



Our recommendation

OPTIONS INSIGHT: BUY LUPIN 2120 CALL BETWEEN 50-51 TARGETS 57-63 STOP LOSS BELOW 44

Technical analysis

Lupin was trading in a very strong bullish trend. The chart clearly indicates a bullish trend where stock is forming higher highs and higher lows. The stock is also near its all time high levels of 2129 which it has formed in October 2015. The stock was consolidating near its all time high levels on 15 min chart and we observed a break out candle. It indicates further upward momentum in the stock. Hence we recommended to Buy Lupin 2120 Call Option.



Disclaimer

I, Ruchi Nahar, SEBI Registered Research Analyst (INH000014544) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified CA, CS and MBA, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverage my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

09.08.2024

